CN110108880A - Fez1自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 - Google Patents
Fez1自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 Download PDFInfo
- Publication number
- CN110108880A CN110108880A CN201910467821.9A CN201910467821A CN110108880A CN 110108880 A CN110108880 A CN 110108880A CN 201910467821 A CN201910467821 A CN 201910467821A CN 110108880 A CN110108880 A CN 110108880A
- Authority
- CN
- China
- Prior art keywords
- reagent
- fez1
- lung cancer
- autoantibody
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 46
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 46
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 46
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 46
- 102100037682 Fasciculation and elongation protein zeta-1 Human genes 0.000 title claims abstract description 45
- 238000001514 detection method Methods 0.000 title claims abstract description 34
- 238000012216 screening Methods 0.000 title claims abstract description 18
- 101710142669 Leucine zipper putative tumor suppressor 1 Proteins 0.000 title claims abstract 15
- 210000002966 serum Anatomy 0.000 claims abstract description 21
- 238000012360 testing method Methods 0.000 claims abstract description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000002965 ELISA Methods 0.000 claims description 4
- 238000001262 western blot Methods 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 238000001179 sorption measurement Methods 0.000 claims 2
- 239000003547 immunosorbent Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 102000019362 Fasciculation and elongation protein zeta 1 Human genes 0.000 description 1
- 108050006773 Fasciculation and elongation protein zeta 1 Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4746—Cancer-associated SCM-recognition factor, CRISPP
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明涉及体外诊断试剂领域，具体涉及FEZ1自身抗体检测试剂在制备肺癌筛查试剂盒中的用途。本发明首次发现肺癌患者血清中FEZ1蛋白的自身抗体水平显著高于健康患者。本发明将检测FEZ1蛋白自身抗体的试剂用于制备肺癌筛查试剂盒，能够实现肺癌的有效筛查。
Description
技术领域
本发明涉及体外诊断试剂领域，具体涉及FEZ1自身抗体检测试剂在制备肺癌筛查试剂盒中的用途。
背景技术
肺癌是世界上最常见的恶性肿瘤之一，其发病率和死亡率呈逐年上升趋势，目前发病率居世界首位，严重威胁着人类健康和生命。
肺癌是一种善于隐匿的疾病，经常在疾病发展到晚期才表现出临床症状，70～80％的肺癌患者在诊断出患有肺癌症状时已是中、晚期，癌细胞已经扩散，错过了最佳治愈时机，五年生存率低。对于早期的肺癌患者，经过及时治疗可大大提高患者的5年及以上生存率和生存质量。因此肺癌的早期诊断和进行有效的筛查至关重要。
肺癌的筛查，是指对那些没有肺癌相关症状的人群进行常规体检，在出现症状前及时发现肺癌。如果可以找到血浆里面的肺癌分子标志物，用于提示临床医生早期对患者采取相关的治疗措施或者决策具有重要的意义。
自身抗体是指机体对自身器官、细胞或细胞成分产生的抗体。目前，某些蛋白的自身抗体已经成为肺癌的标记物，如：p53、NY-ESO-1、CYFRA等等(Tang Z-M，Ling Z-G，WangC-M，Wu Y-B，Kong J-L(2017)Serum tumor-associated autoantibodies as diagnosticbiomarkers for lung cancer：A systematic review and meta-analysis.PLoS ONE 12(7)：e0182117)。
FEZ1(fasciculation and elongation protein zeta 1，Ensembl：ENSG00000149557)是秀丽隐杆线虫unc-76蛋白同源物，为正常轴突束和轴突束内伸长所必需的蛋白。目前尚未见FEZ1蛋白自身抗体的相关报道，也未见其与肺癌相关的现有技术。
发明内容
本发明的目的在于提供一种新的自身抗体类的肺癌标志物，以及该标志物的检测试剂在制备肺癌筛查试剂盒中的用途。
本发明的技术方案包括：
检测FEZ1蛋白自身抗体的试剂在制备肺癌筛查试剂盒中的用途。
如前述的用途，所述检测FEZ1蛋白自身抗体的试剂为酶联免疫吸附试验用试剂或联免疫分析试剂。
如前述的用途，所述检测FEZ1蛋白自身抗体的试剂为western blot试剂。
如前述的用途，所述检测FEZ1蛋白自身抗体的试剂为蛋白芯片检测方法用试剂。
如前述的用途，所述检测FEZ1蛋白自身抗体的试剂是检测人血清中FEZ1蛋白自身抗体的试剂。
一种肺癌筛查试剂盒，它包括用于检测FEZ1蛋白自身抗体的试剂。
如前述的试剂盒，所述检测FEZ1蛋白自身抗体的试剂为酶联免疫吸附试验用试剂或酶联免疫分析试剂。
如前述的试剂盒，所述检测FEZ1蛋白自身抗体的试剂为western blot试剂。
如前述的试剂盒，所述检测FEZ1蛋白自身抗体的试剂为蛋白芯片检测方法用试剂。
如前述的试剂盒，所述检测FEZ1蛋白自身抗体的试剂是检测人血清中FEZ1蛋白自身抗体的试剂。
本发明提供了一种新的肺癌筛查标记物和一种新的肺癌筛查试剂盒，能够实现肺癌的有效筛查；且能以血清作为检测样品，对患者伤害很低。本发明具备良好的应用前景。
显然，根据本发明的上述内容，按照本领域的普通技术知识和惯用手段，在不脱离本发明上述基本技术思想前提下，还可以做出其它多种形式的修改、替换或变更。
以下通过具体实施方式对本发明的上述内容再作进一步的详细说明。但不应将此理解为本发明上述主题的范围仅限于以下的实例。凡基于本发明上述内容所实现的技术均属于本发明的范围。
下文中“FEZ1自身抗体”，指的是“FEZ1蛋白自身抗体”。
附图说明
图1：肺癌患者(LC)、健康对照(NC)血清浆中FEZ1自身抗体水平对比。
图2：肺癌患者(LC)与健康对照(NC)ROC分析。
具体实施方式
实施例1血浆中FEZ1自身抗体与肺癌的关系
一、临床资料
选取肺癌患者30例，健康对照30例，基本信息如下：
| 基本信息 | 肺癌患者 | 健康对照 |
| 人数 | 30 | 30 |
| 年龄 | 58±10.5 | 42±8.9 |
| 男性比例 | 20(66.7％) | 13(46.7％) |
二、检测原理
HuProtTM人类蛋白质定制芯片上固定有FEZ1蛋白，加血清孵育后，血清中FEZ1自身抗体(主要包括IgG、IgM型抗体，也有一些其它类型的抗体)会结合上去，清洗去除未结合的抗体和其它蛋白质，再用抗人IgM荧光标记二抗(cy5标记，呈现红色)和抗人IgG荧光二抗(cy3标记，呈现绿色)检测，通过荧光扫描仪读取信号，信号的强弱与抗体的亲和力和数量呈正相关。
三、方法
1)复温：将芯片从-80℃冰箱取出，置于4℃冰箱复温半小时，然后置于室温复温15min；
2)封闭：复温后的芯片，固定14个blocks围栏，固定好之后，向每个block中加入封闭液，并放置侧摆摇床上，室温封闭3hr；
3)血清样本孵育：封闭完成后，倒尽封闭液，然后迅速加入预先准备好的血清孵育液，每张芯片可孵育14个血清样本，每个血清样本的上样体积为200μL，侧摆摇床20rpm，4℃过夜孵育(血清样本先放在4℃层析柜冻融，加孵育液以1∶50比例稀释，得血清孵育液)；
4)清洗：将芯片及芯片围栏一同取出，吸去样本，然后迅速加入等体积的PBST，如此循环数次，保证在拆除芯片围栏时血清样本间无交叉污染。拆除芯片围栏后，将芯片置于加有清洗液的芯片清洗盒，水平摇床，室温80rpm，清洗3次，每次10min；
5)二抗孵育：将芯片转移到加入了3mL二抗孵育液的孵育盒中，侧摆摇床40rpm，避光，室温1hr；
6)清洗：将芯片取出(注意不能触及或划破芯片的上表面)，置于加有清洗液的芯片清洗盒，水平摇床，室温80rpm，清洗3次，每次10min。完成后用ddH2O清洗2次，每次10min；
7)干燥；
8)扫描：使用晶芯LuxScan 10K微阵列芯片扫描仪扫描；
9)数据提取：将对应GAL文件(记录了芯片中蛋白所在位置)打开，将芯片图像和GAL文件每个阵列整体对齐，按下自动对齐按钮，提取数据并保存。
四、结果
肺癌患者血浆中的FEZ1自身抗体的平均表达水平为16.4SNR(荧光信号相对定量比值)，健康对照血浆中FEZ1自身抗体的平均表达水平为10.0SNR。肺癌组与健康对照组(p＜0.05)相比均有统计学意义(图1)。肺癌组与健康对照的ROC分析结果特异性为96.5％，敏感性为31.0％(图2)，表明FEZ1自身抗体可特异地区分肺癌与肺部良性疾病和健康对照。
由以上结果可知，肺癌患者与非肺癌患者的血清中FEZ1自身抗体的水平差异显著，通过检测血清中FEZ1自身抗体的水平，能够达到肺癌筛查的目的。
实施例2本发明的检测试剂盒的组成及其使用方法
一、试剂盒组成
检测试剂盒(14人份)：
二、试剂盒使用方法
同实施例1第三部分——“血清中FEZ1自身抗体的检测”。
本发明的试剂盒可以通过检测血清中FEZ1自身抗体的水平，可以筛查待检人群患肺癌的风险：若FEZ1自身抗体水平高(相对于健康人而言)，则患肺癌的风险高，若FEZ1自身抗体水平低，则患肺癌的风险低。可用于临床肺癌的辅助诊断，为患者采取相关的治疗措施或者决策提供有效的依据，临床应用前景良好。
Claims (10)
1.检测FEZ1蛋白自身抗体的试剂在制备肺癌筛查试剂盒中的用途。
2.如权利要求1所述的用途，其特征在于，所述检测FEZ1蛋白自身抗体的试剂为酶联免疫吸附试验用试剂或联免疫分析试剂。
3.如权利要求1所述的用途，其特征在于，所述检测FEZ1蛋白自身抗体的试剂为western blot试剂。
4.如权利要求1所述的用途，其特征在于，所述检测FEZ1蛋白自身抗体的试剂为蛋白芯片检测方法用试剂。
5.如权利要求1～4任一所述的用途，其特征在于，所述检测FEZ1蛋白自身抗体的试剂是检测人血清中FEZ1蛋白自身抗体的试剂。
6.一种肺癌筛查试剂盒，其特征在于，它包括用于检测FEZ1蛋白自身抗体的试剂。
7.如权利要求6所述的试剂盒，其特征在于，所述检测FEZ1蛋白自身抗体的试剂为酶联免疫吸附试验用试剂或酶联免疫分析试剂。
8.如权利要求6所述的试剂盒，其特征在于，所述检测FEZ1蛋白自身抗体的试剂为western blot试剂。
9.如权利要求6所述的试剂盒，其特征在于，所述检测FEZl蛋白自身抗体的试剂为蛋白芯片检测方法用试剂。
10.如权利要求5～9任一所述的试剂盒，其特征在于，所述检测FEZ1蛋白自身抗体的试剂是检测人血清中FEZ1蛋白自身抗体的试剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910467821.9A CN110108880A (zh) | 2019-05-30 | 2019-05-30 | Fez1自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910467821.9A CN110108880A (zh) | 2019-05-30 | 2019-05-30 | Fez1自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110108880A true CN110108880A (zh) | 2019-08-09 |
Family
ID=67493295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910467821.9A Pending CN110108880A (zh) | 2019-05-30 | 2019-05-30 | Fez1自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110108880A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110632312A (zh) * | 2019-10-25 | 2019-12-31 | 四川大学华西医院 | A1cf自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 |
| CN110850088A (zh) * | 2019-12-06 | 2020-02-28 | 四川大学华西医院 | Gtf2ird2自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1852974A (zh) * | 2003-06-09 | 2006-10-25 | 密歇根大学董事会 | 用于治疗和诊断癌症的组合物和方法 |
| CN101999001A (zh) * | 2008-02-08 | 2011-03-30 | 米迪缪尼有限公司 | 疾病标志物及其用途 |
| US20140135225A1 (en) * | 2012-11-15 | 2014-05-15 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Spe | Biomarkers for disease activity and clinical manifestations systemic lupus erythematosus |
| US20180017554A1 (en) * | 2014-05-09 | 2018-01-18 | Protagen Ag | Marker sequences for the diagnosis and stratification of systemic sclerosis patients |
-
2019
- 2019-05-30 CN CN201910467821.9A patent/CN110108880A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1852974A (zh) * | 2003-06-09 | 2006-10-25 | 密歇根大学董事会 | 用于治疗和诊断癌症的组合物和方法 |
| CN101999001A (zh) * | 2008-02-08 | 2011-03-30 | 米迪缪尼有限公司 | 疾病标志物及其用途 |
| US20140135225A1 (en) * | 2012-11-15 | 2014-05-15 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Spe | Biomarkers for disease activity and clinical manifestations systemic lupus erythematosus |
| US20180017554A1 (en) * | 2014-05-09 | 2018-01-18 | Protagen Ag | Marker sequences for the diagnosis and stratification of systemic sclerosis patients |
Non-Patent Citations (2)
| Title |
|---|
| CDI-LAB.COM: "HuProt v3 block 7", 《HTTPS://COLLECTION.CDI-LAB.COM/PUBLIC/GAL/3/7?PAGE=10》 * |
| 裴露: "基于SEREX技术及Oncomine数据库对肺癌相关抗原的筛选与鉴定", 《中国优秀硕士学位论文全文数据库》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110632312A (zh) * | 2019-10-25 | 2019-12-31 | 四川大学华西医院 | A1cf自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 |
| CN110632312B (zh) * | 2019-10-25 | 2021-08-20 | 四川大学华西医院 | A1cf自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 |
| CN110850088A (zh) * | 2019-12-06 | 2020-02-28 | 四川大学华西医院 | Gtf2ird2自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 |
| CN110850088B (zh) * | 2019-12-06 | 2021-08-20 | 四川大学华西医院 | Gtf2ird2自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110108879A (zh) | Erp27自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 | |
| CN110108877A (zh) | Fam172a自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 | |
| CN110108880A (zh) | Fez1自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 | |
| CN110412276A (zh) | Pde9a自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 | |
| CN110456064A (zh) | Sars2自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 | |
| CN110412274A (zh) | C6orf106自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 | |
| CN110456083A (zh) | Prkcz自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 | |
| CN110456067A (zh) | Ehd2自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 | |
| CN110412279A (zh) | Klc3自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 | |
| CN110412281A (zh) | Begain自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 | |
| CN110456066A (zh) | Dbnl自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 | |
| CN110412298A (zh) | Fcrl4自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 | |
| CN110412273A (zh) | Caap1自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 | |
| CN110456068A (zh) | Xirp1自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 | |
| CN110456080A (zh) | C14orf37自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 | |
| CN110412270A (zh) | Ssna1自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 | |
| CN110456070A (zh) | Hace1自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 | |
| CN110412299A (zh) | Hectd3自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 | |
| CN110514842A (zh) | Dynll1自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 | |
| CN110456082A (zh) | Pde4dip自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 | |
| CN110456085A (zh) | Syt12自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 | |
| CN110456063A (zh) | Tpm2自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 | |
| CN110456061A (zh) | Rundc3a自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 | |
| CN110108878A (zh) | Eif2s1自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 | |
| CN110456079A (zh) | Tapbp自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |